GO
| HSI1 | 24,280.56 | +240.22 | 98.26B |
| HSCEI1 | 8,128.97 | +77.30 | 26.51B |
| Back Zoom + Zoom - Block Traded | |
|
2026-09-29 17:28:38 HSBC Global Investment Research issued a research report listing investment ratings and target prices for China pharmaceutical and biotechnology stocks as follows: Stock | Investment Rating | TP HENGRUI PHARMA (01276.HK) | Buy | HKD73.7 -> HKD72.5 HANSOH PHARMA (03692.HK) | Buy | HKD49.5 SBP GROUP (01177.HK) | Buy | HKD8.5 -> HKD8 CSPC PHARMA (01093.HK) | Buy | HKD9.25 -> HKD11.7 FOSUN PHARMA (02196.HK) | Hold | HKD18.3 -> HKD19.6 LIVZON PHARMA (01513.HK) | Hold | HKD29 -> HKD22.3 CMS (00867.HK) | Buy | HKD17 -> HKD15.45 BeOne Medicines Ltd. (ONC.US) | Buy | USD385 INNOVENT BIO (01801.HK) | Buy | HKD130 AKESO (09926.HK) | Buy | HKD163 SKB BIO (06990.HK) | Buy | HKD584 KEYMED BIO-B (02162.HK) | Buy | HKD107 ~ AASTOCKS Financial News Website: www.aastocks.com | |